647 related articles for article (PubMed ID: 19561534)
1. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
2. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
3. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine.
Huang Y; Fayad R; Smock A; Ullrich AM; Qiao L
Cancer Res; 2005 Aug; 65(15):6990-9. PubMed ID: 16061685
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
5. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
[TBL] [Abstract][Full Text] [Related]
6. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
7. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
8. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
Saha A; Chatterjee SK
Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
[TBL] [Abstract][Full Text] [Related]
9. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
10. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
11. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
Shirai M; Arichi T; Nishioka M; Nomura T; Ikeda K; Kawanishi K; Engelhard VH; Feinstone SM; Berzofsky JA
J Immunol; 1995 Mar; 154(6):2733-42. PubMed ID: 7533182
[TBL] [Abstract][Full Text] [Related]
12. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
Hung CF; Calizo R; Tsai YC; He L; Wu TC
Vaccine; 2007 Jan; 25(1):127-35. PubMed ID: 16930783
[TBL] [Abstract][Full Text] [Related]
13. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
14. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.
Huarte E; Sarobe P; Lu J; Casares N; Lasarte JJ; Dotor J; Ruiz M; Prieto J; Celis E; Borrás-Cuesta F
Clin Cancer Res; 2002 Jul; 8(7):2336-44. PubMed ID: 12114438
[TBL] [Abstract][Full Text] [Related]
15. Clearance of Chlamydia pneumoniae infection in H-2 class I human leucocyte antigen-A2.1 monochain transgenic mice.
Tammiruusu A; Haveri A; Pascolo S; Lahesmaa R; Stevanovic S; Rammensee HG; Sarvas M; Puolakkainen M; Vuola JM
Scand J Immunol; 2005 Aug; 62(2):131-9. PubMed ID: 16101819
[TBL] [Abstract][Full Text] [Related]
16. MMP11: a novel target antigen for cancer immunotherapy.
Peruzzi D; Mori F; Conforti A; Lazzaro D; De Rinaldis E; Ciliberto G; La Monica N; Aurisicchio L
Clin Cancer Res; 2009 Jun; 15(12):4104-13. PubMed ID: 19509157
[TBL] [Abstract][Full Text] [Related]
17. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.
Pajot A; Michel ML; Fazilleau N; Pancré V; Auriault C; Ojcius DM; Lemonnier FA; Lone YC
Eur J Immunol; 2004 Nov; 34(11):3060-9. PubMed ID: 15468058
[TBL] [Abstract][Full Text] [Related]
18. A novel mouse model for immunogenic evaluation of human HBV vaccines.
Guo Y; Ren D; He X; Wang F; Jiang L; Song S; He Y; Sun S
Vaccine; 2009 Sep; 27(41):5692-9. PubMed ID: 19615480
[TBL] [Abstract][Full Text] [Related]
19. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
20. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
